Clinical Trials Logo

Clinical Trial Summary

This study hopes to improve the investigators understanding of how the immune system acts in allergic contact dermatitis. In order to reach this goal, normal volunteers, who are suspected of having allergic contact dermatitis, will be patch tested for the fifteen most common allergens. Then, biopsies will be taken of the skin at the sites where the there is a positive reaction to the allergen. Also, small biopsies will be taken from an area that received a patch but no allergen and an area that did not receive a patch to serve as controls. In a second stage of the study, volunteers will receive patches with the allergen to which they demonstrated an allergic response. More biopsies will be taken, over three designated time points. The biopsied skin samples will then be studied in a laboratory.


Clinical Trial Description

Allergic contact dermatitis is a term for a skin reaction resulting from exposure to specific substances that come into contact with skin that is hypersensitive (allergic) to the substance. These substances are called "allergens." Some common allergens are nickel, rubber, dyes, poison ivy, poison oak and other related plants. These allergens do not cause a skin reaction in most individuals, but for some, once the skin becomes sensitive or allergic to the substance, any exposure to that specific allergen will produce a rash that may consist of redness, swelling and blisters. This rash may become worse with each exposure to the allergen. The skin reaction results from two phases. In the induction phase, initial exposure to the allergen occurs. The body recognizes the allergen as foreign and the immune system, which is the body's primary line of defense against infections and other things perceived as foreign to the body, mounts an immune response against the body, itself. During this immune response, cells specific to the allergen are activated. In the second phase, the elicitation phase, the skin is again exposed to the allergen and an immune response occurs, as the cells that are specific to the allergen attack the skin, leading to the rash. In order to diagnose allergic contact dermatitis, a clinician will discuss the materials that touch the patient's skin at work and home and perform patch tests. In a patch test, a very small amount of the suspected allergens are applied to the skin for a fixed time. After that designated time, the clinician will determine whether a reaction has occurred to the applied allergens. Currently, the main treatment for allergic contact dermatitis is avoidance of the allergen.

This study hopes to improve our understanding of how the immune system acts in allergic contact dermatitis. In order to reach this goal, normal volunteers, who are suspected of having allergic contact dermatitis, will be patch tested for the fifteen most common allergens. Then, biopsies will be taken of the skin at the sites where the there is a positive reaction to the allergen. Also, small biopsies will be taken from an area that received a patch but no allergen and an area that did not receive a patch to serve as controls. In a second stage of the study, volunteers will receive patches with the allergen to which they demonstrated an allergic response. More biopsies will be taken, over three designated time points. The biopsied skin samples will then be studied in a laboratory by methods such as immunohistochemistry and microarray analysis, which will help define the progression of the immune reaction in allergic contact dermatitis. The rationale for the study is to better understand how the immune system is activated to produce the rash of allergic contact dermatitis, so that treatments can target the cells that are involved in the activation. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01546298
Study type Observational
Source Rockefeller University
Contact
Status Completed
Phase
Start date January 2012
Completion date December 14, 2012

See also
  Status Clinical Trial Phase
Completed NCT03945760 - Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects Early Phase 1
Not yet recruiting NCT05498467 - The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis Phase 3
Active, not recruiting NCT03680131 - Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis Phase 2
Recruiting NCT05535738 - Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation Phase 2/Phase 3
Recruiting NCT06191627 - Patient Experience and Quality of Patch Testing on the Legs vs Back N/A
Completed NCT00867607 - Safety, Tolerability, and Efficacy of 21 Days Dermal Application of MRX-6 on Mild to Moderate Contact Dermatitis Phase 1/Phase 2
Recruiting NCT00445029 - Pathophysiological Study of Allergic Contact Dermatitis to Para-Phenylenediamine (PPD). Analysis of Cellular and Molecular Targets in Skin Inflammation N/A
Completed NCT04365140 - MicroRNA-126 and Its Target VCAM-1Dermatitis to Nickel
Recruiting NCT05991674 - A Prospective Study to Investigate Contact Sensitization Using Classic and Machine Learning Techniques
Completed NCT00931242 - Study of Apremilast in Atopic or Contact Dermatitis Phase 2
Completed NCT01798589 - Bioequivalence of Ethylenediamine Dihydrochloride Study Phase 4
Completed NCT05339750 - Allergy Skin Patch Artificial Intelligence (AI) N/A
Recruiting NCT03935971 - The Effects of Dupilumab on Allergic Contact Dermatitis Phase 4
Completed NCT01797562 - Clinical Evaluation of T.R.U.E. Test Allergens in Children an Adolescents N/A
Not yet recruiting NCT05858723 - Repeated Open Application Test (ROAT) Study With Hydroperoxides of Linalool N/A
Completed NCT02534441 - Epidemiology and Co-Reactivity of Novel Surfactant Allergens N/A
Not yet recruiting NCT01413477 - Nickel Desensitization Using Topical Therapy N/A
Completed NCT00132600 - Clinical Evaluation of Bacitracin Phase 2
Completed NCT00133341 - Clinical Evaluation of the 3 Allergens: Methyldibromoglutharonitrile, Parthenolide and Goldnatriumthiosulphate Phase 2
Completed NCT03902392 - Red Grape Polyphenol Oral Administration to Women Affected by Nickel-mediated Allergic Contact Dermatitis N/A